We have recently shown that STAT5 expression levels increase during CML progression and that elevated activated STAT5 levels account for a reduced responsiveness to BCR-ABL1 tyrosine kinase inhibitor (TKI) therapy [30]. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.